Complaint
Products Name: Retatrutide
Trade Name: LY-3437943
CAS No.:2381089-83-2
Molecular Formula: C221H342N46O68
Molecular Weight: 4731.33g/mol
Sequence:Tyr-{Aib}-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-{α-Me-Leu}-Leu-Asp-Lys-{diacid-C20-gamma-Glu-(AEEA)-Lys}-Ala-Gln-{Aib}-Ala-Phe-Ile-Glu-Tyr-Leu-Leu-Glu-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2
Appearance: White Lyophilized powder
Reconstitution: Required
Storage: After reconstitution store at 2°C - 8°C
What is Retatrutide?
Retatrutide, also known as LY-3437943, is a novel medication developed by the pharmaceutical company Eli Lilly with significant potential for the treatment of obesity and diabetes. This injectable drug, soon to be approved by the FDA, is classified as a GGG tri-agonist, GLP-1/GIP/glucagon tri-agonist. It shares similarities with existing weight-loss medications like tirzepatide and semaglutide but offers enhanced efficacy. When used in conjunction with a proper diet, regular exercise, and lifestyle modifications, Retatrutide can help improve weight loss outcomes and address obesity-related comorbidities such as diabetes and hypertension.
Retatrutide surpasses other weight-loss medications in terms of effectiveness. It exerts its therapeutic effects through three crucial mechanisms:
Gastric inhibitory polypeptide receptor (GIPR) agonist: Acting as a GIP receptor agonist, Retatrutide enhances appetite suppression and prevents fat accumulation, leading to reduced energy intake and increased energy expenditure.
Glucagon-like peptide-1 receptor (GLP-1R) agonist: By improving insulin release from the pancreas and reducing the release of glucagon (a hormone that elevates blood sugar levels), Retatrutide aids in weight reduction and enhances blood glucose control.
Glucagon receptor (GR) agonist: Retatrutide improves blood sugar levels by reducing the release of glucagon. It also decreases food intake and increases energy expenditure, resulting in weight loss.
Benefits of GLP-1 agonists:
Slows down the emptying of food from the stomach
Prevents excessive sugar production by the liver
Stimulates increased insulin production by the pancreas in response to high blood sugar levels
Helps regulate blood glucose levels
Reduces post-meal hyperglycemia
Lowers fasting insulin and fasting glucose levels
Decreases hemoglobin A1c levels
Suppresses appetite, reduces calorie intake, and inhibits weight gain
Lowers triglyceride levels and oxidative stress associated with high LDL cholesterol
Induces weight loss, particularly at higher doses in obese patients
Decreases leptin levels and increases leptin sensitivity
Promotes the conversion of white fat to brown fat
| retatrutide | 2381089-83-2 |
| semaglutide | 910463-68-2 |
| Tirzepatide | 2023788-19-2 |
| GHK-Cu (Copper Peptide) | 49557-75-7 |
| NAD+ |
